Ctl inducer composition

Abstract

The present invention provides a CTL inducer composition which comprises one or more peptides selected from the group consisting of the peptides of SEQ ID NOS: 1 to 27 in the Sequence Listing, and can be used for the treatment or prevention of cancer or a hepatitis C virus-related disease in two or more patient groups selected from the group consisting of an HLA-A2 positive patient group, an HLA-A24 positive patient group, an HLA-A26 positive patient group, and an HLA-A3 supertype positive patient group.

1 - 13 . (canceled) 
     
     
         14 . A method for the treatment of cancer in an HLA-A2 positive patient, which comprises administering a cytotoxic T lymphocyte inducer composition which comprises one or more peptides selected from the group consisting of EGFR-800 (SEQ ID NO: 1), Lck-488 (SEQ ID NO: 3), SART2-93 (SEQ ID NO: 7), SART3-109 (SEQ ID NO: 8), Lck-90 (SEQ ID NO: 19), and SART3-511 (SEQ ID NO: 23) to an HLA-A2 positive patient. 
     
     
         15 . The method of  claim 14 , wherein the administration of the cytotoxic T lymphocyte inducer composition comprises intradermal administration or subcutaneous administration. 
     
     
         16 . The method of  claim 14 , wherein the one or more peptides are administered in an amount of 0.1 to 5 mg. 
     
     
         17 . A method for the treatment of cancer in an HLA-A3 supertype positive patient, which comprises administering a cytotoxic T lymphocyte inducer composition which comprises one or more peptides selected from the group consisting of EGFR-800 (SEQ ID NO: 1), SART2-93 (SEQ ID NO: 7), and SART3-109 (SEQ ID NO: 8) to an HLA-A3 supertype positive patient. 
     
     
         18 . The method of  claim 17 , wherein the HLA-A3 supertype is HLA-A11 or HLA-A31. 
     
     
         19 . The method of  claim 17 , wherein the administration of the cytotoxic T lymphocyte inducer composition comprises intradermal administration or subcutaneous administration. 
     
     
         20 . The method of  claim 17 , wherein the one or more peptides are administered in an amount of 0.1 to 5 mg.